Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients.

Background: The management of Crohn's disease patients with perianal lesions and anti-TNF failure is challenging.

Aims: To assess the effectiveness of vedolizumab in perianal Crohn's disease and the predictors of success in a real-life cohort.

Methods: We conducted a nationwide multicentre cohort study in patients with perianal Crohn's disease who received vedolizumab.

Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.

Background & Aims: Teduglutide, a GLP-2-analog, has proven effective in two placebo-controlled studies in reducing parenteral support (PS) in patients with short bowel syndrome-associated intestinal failure (SBS-IF) after 24 weeks. The aim of this study was to describe in a real-life situation the effects of teduglutide treatment and their predictive factors.

Methods: We included 54 consecutive SBS-IF patients treated with teduglutide in France for at least 6 months from 10 expert centers.

Deep remission on magnetic resonance imaging impacts outcomes of perianal fistulizing Crohn's disease.

Background: The long-term management of perianal Crohn's disease for patients on anti-TNF-α therapy remains challenging.

Aim: To evaluate the long-term course and complications of patients with perianal fistulas treated with anti-TNF-α based on their clinical remission and healing on MRI.

Methods: Patients were evaluated clinically and by MRI.

Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study.

Background: Extraintestinal manifestations (EIM) have been associated with more severe course of inflammatory bowel disease. The aim was to study the frequency of EIM in pediatric- and elderly-onset Crohn's disease (CD) and the factors associated with EIM and their impact on long-term disease outcome.

Methods: Pediatric- (age at diagnosis younger than 17 years) and elderly-onset CD patients (age at diagnosis 60 years or older) from a prospective population-based registry (EPIMAD) were recruited.

Impact of age at diagnosis on natural history of patients with elderly-onset ulcerative colitis: A French population-based study.

Background: Recent population-based study of elderly-onset Crohn's disease patients reported age-related differences in disease phenotype and outcome.

Aims: The aim was to assess the impact of age at diagnosis on natural history of elderly-onset ulcerative colitis patients with emphasis on disease presentation, phenotype and treatment.

Methods: Elderly-onset patients with ulcerative colitis (≥60 years at diagnosis) registered in a French population-based Registry EPIMAD (1988-2006) were included.